Addressing the Problem of Drug-Resistant Cancer

-

Meet Johnathan Whetstine, PhD.
 
Cancer cells that stop responding to treatment (drug resistance) are a common cause of cancer deaths. Researchers are trying to understand how to treat resistance, and/or prevent it in the quest for the next generation of cancer therapies that can save lives. One such researcher, Johnathan Whetstine, PhD and his team in the Whetstine Laboratory at the Mass General Center for Cancer Research is studying how cancer cells become drug-resistant. They recently uncovered a protein that generates specific DNA fragments containing genes that cause cancer cells to become resistant to chemotherapy. This allows replicating cancer cells to grow and defend themselves against previously effective treatments. We all know how devious cancer cells are in trying to outsmart treatments.
The Whetstine Laboratory’s discovery was the first of its kind, and provides a new way to understand how cancer cells change their DNA content and potentially acquire the ability to become treatment resistant. In fact, their discovery identified a new protein to evaluate in tumors and directly relates to cancer cell response to therapy. Most recently, Dr. Whetstine’s group used a drug to target the protein and was able to block the extra DNA pieces associated with drug resistance. These findings illustrate the importance of evaluating this protein in tumors and demonstrate that this process does not occur randomly but can be directed and targeted by proteins within the cell. Dr. Whetstine’s group is currently uncovering additional genes and conditions that can generate extra DNA pieces involved in cancer cell drug resistance. This work holds promise for the development of new strategies to block resistances to chemotherapies and targeted therapies with broad and profound implications for many different types of cancer.
Tumor cells contain extra copies of DNA that ultimately contribute to their lack of response to chemotherapeutics and aggressive behavior. The Whetstine Laboratory is working to uncover the genes and proteins that promote copy gains of DNA regions and stimulate resistance to help identify novel drug targets associated with aggressive drug resistant cancer and provide novel biomarkers to evaluate in patients during the course of therapy so that resistance may be predicted earlier. The Whetstine Laboratory has now unlocked a way to better understand copy gains related to tumorigenesis and have firmly established that these events are regulated.
The Whetstine’s Laboratory is another of the research programs that needs philanthropic support – in this case to investigate how treatment resistance occurs, how we can think about blocking drug resistance and how we can help identify patients who are most vulnerable to emerging drug resistance. Their studies are currently aimed at addressing this question in lung cancer, ovarian cancer, myeloma, breast cancer and neuroblastoma.
One of the Disruptive Dozen
The culture of innovation at Massachusetts General Hospital and Brigham and Women’s Hospital —throughout all of Partners HealthCare and collaborating institutions such as Dana-Farber Cancer Institute—naturally fosters a good deal of discussion about new “disruptive” technologies and which ones will have the biggest impact in bringing novel complex health care products and services to greater levels of affordability and accessibility. The mission of Partners clinicians and researchers to provide the best care for patients drives a continuous dialogue on what state-of-the-art medical technologies are just over the horizon. The Disruptive Dozen was created to identify and rank the most disruptive technologies that Partners leading faculty feel will break through over the next decade in cancer care.
Johnathan Whetstine was recognized for his work at the Partners World Medical Innovation Forum in April as one of the most promising technologies (number 5) that will have significant impact on cancer care in the next 10 years. He and his wife are also our friends, and fellow MGH one hundred honorees. #gratitude
 

 

 

 

 

Popular posts from this blog

A Bowl of Gratitude

-
Image
I was introduced recently to Lynne Sarnoff-Christensen by her cousin, and my friend Jeffrey Cohen. You see, she makes pottery and well, more specifically she make “bowls of gratitude”. So of course, Jeffrey knew that I would hit it off with Lynne because he knows I live a life full of gratitude. Another friend, Keith Spiro said I just had to buy a bowl – so I did. The idea is to put notes in the bowl about things you are grateful for. So it’s my new thing. I’ve long been a fan of Shawn Achor and I’ve gotten into the habit of writing down things that I am grateful for. So this bowl of gratitude will be where I put my notes. And I will encourage my family to also add their notes to the bowl. We have a tradition on Thanksgiving to go around the table before we dig in to our meal, to share what we are thankful for. We shouldn’t just do this at Thanksgiving! When I called Lynne, she explained her philosophy and I get it: “You didn’t get from there to here without people believ...
Read more

The Power of Community: The White Ribbon Project

-
Image
The Greek meaning of evangelist is "bringing the good news." It's why I call my podcast the Research Evangelist Podcast. I love to share stories about people in life sciences who are doing amazing work to advance cancer research. And it's why The White Ribbon Project has captured my attention. The White Ribbon Project is a grassroots movement of lung cancer patients, advocates, clinicians, researchers friends and families with a mission to change the public perception of lung cancer by spreading awareness that anyone with lungs can get lung cancer. No one deserves lung cancer whether you smoked or not. But lung cancer is not just a smokers disease, as more and more people are getting lung cancer with no smoking history. The White Ribbon Project is proving that the power of a community that cares can be unleashed by individuals who wanted to make a difference - people that didn't set out to start a movement. It's because their story is so sincere and authentic...
Read more

Time to Move Beyond the Ribbons?

-
This past week, I had the pleasure of meeting Massachusetts Senator Ed Markey and Harvard Medical School Professor of Genetics, Dr. Fred Alt. They were both in Washington, DC for the presentation of the 2015 NFCR Szent-Györgyi Prize for Progress in Cancer Research, which was awarded to Dr. Alt and keynoted by Sen. Markey.   The common theme I heard from both of these distinguished leaders was captured in a Huffington Post article written by Sam Stein , who attended the event . Stein succinctly wrote that “U.S. Science has never been more imperiled”. He noted that the lack of funding for basic scientific research not only prevents new discoveries, but it also means that we are losing promising scientists whose work can’t get funded.    10 years ago, nearly a third of qualified research was funded by NIH.   Now that number is only 14% (actually even lower for oncology, near 9%).   As Sen. Markey said, “sadly, support for scientific research in our countr...
Read more